HSA | FSA CARDS ARE NOW ACCEPTED

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, compounded semaglutide is not being eliminated. The FDA has issued guidance allowing compounded semaglutide through licensed 503A pharmacies when brand-name alternatives face shortages, and this pathway remains available as of 2024. However, regulatory frameworks continue evolving, making it essential for patients to understand their options and the role of provider guidance.

For individuals considering GLP-1 therapy, clarity on compounded versus brand medications directly affects access, cost, and clinical decision-making. PlexusDx emphasizes precision wellness by helping patients understand not just medication availability but also individual factors—including genetic predispositions in peptide pathways—that may inform more personalized conversations with their healthcare team.

The FDA's Position on Compounded Semaglutide

The FDA issued guidance in 2023 permitting compounded semaglutide from licensed 503A compounding pharmacies under specific conditions, primarily when brand-name supply is insufficient. This guidance did not ban compounding but instead clarified the regulatory pathway. The agency continues monitoring quality and safety across compounded GLP-1 products in the market.

Compounded medications prepared by 503A pharmacies differ significantly from mass-manufactured brand drugs. 503A compounders operate under state pharmacy board oversight and USP standards, while 503B compounders (outsourcing facilities) face FDA manufacturing regulations. PlexusDx exclusively sources from licensed 503A pharmacies to maintain compliance with current FDA guidance and state regulations.

Key Differences: Compounded vs. Brand Semaglutide

Understanding the distinctions between compounded and brand-name semaglutide helps patients and providers evaluate which option aligns with individual clinical needs, access constraints, and regulatory preferences. Both pathways carry distinct considerations regarding supply, oversight, cost, and insurance coverage that warrant careful discussion with a qualified healthcare provider.

Feature Brand Semaglutide (Ozempic/Wegovy) Compounded Semaglutide (503A)
Manufacturing oversight FDA-regulated drug manufacturer State pharmacy board + USP standards
Supply stability Subject to manufacturing constraints Compounded per individual prescription
Typical cost range $900-1,500+ per month $149 per month at PlexusDx
Insurance coverage Often covered; varies by plan Rarely covered; patient-pay typical
Regulatory basis FDA approval (NDA) FDA guidance for 503A compounding

Why Regulatory Scrutiny Continues

The FDA maintains heightened oversight of GLP-1 compounding due to past supply chain issues and quality concerns. Recent enforcement actions targeted certain compounders, underscoring that not all compounded products meet the same standards. This regulatory attention reflects the agency's commitment to patient safety, not an intent to eliminate the compounding pathway entirely.

Patients choosing compounded semaglutide should verify their pharmacy holds valid 503A licensure, follows USP standards, and maintains appropriate quality documentation. Working with a healthcare provider experienced in GLP-1 therapy—whether brand or compounded—ensures appropriate clinical monitoring and dose optimization.

Evaluating Your GLP-1 Options: Clinical and Individual Factors

Choosing between compounded and brand semaglutide involves weighing access, cost, clinical evidence, and individual medical history. Neither option guarantees specific outcomes; rather, each offers distinct pathways that may align differently with a patient's circumstances, provider relationships, and treatment goals. A qualified healthcare provider should guide this evaluation.

Beyond medication source, individual factors—including metabolic markers, genetic predispositions in peptide pathways, and previous medication responses—can inform a more nuanced conversation with your provider. The Precision Peptide Genetic Test may help provide context around genetic variants associated with GLP-1 receptor function and metabolic response, supporting a more personalized treatment discussion.

How PlexusDx Supports a More Personalized Approach

PlexusDx emphasizes that understanding compounded semaglutide's regulatory position is just one part of precision GLP-1 care. Individual genetic factors—such as variants in GLP1R (rs6923761) and GIPR (rs1800437) genes—may help provide context around how peptide-based therapies could theoretically influence metabolic pathways. This information should be interpreted with a qualified healthcare provider as one data point among many.

The Precision Peptide Genetic Test examines predispositions in peptide genetic pathways relevant to GLP-1 and GLP-1/GIP dual mechanisms. It does not predict exact medication response or guarantee outcomes; rather, it reveals genetic variants that may correlate with published research on peptide pathway function. This nuanced insight can support a more informed conversation between you and your provider regarding treatment approach.

When evaluating compounded semaglutide or other GLP-1 options, combining regulatory awareness, cost and access considerations, clinical evidence review, and individual biomarker context creates a fuller picture. PlexusDx supports patients in accessing these multiple layers of information so conversations with healthcare providers can be more grounded in personalized, evidence-informed decision-making.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide legal and safe?

Compounded semaglutide from licensed 503A pharmacies is legal under FDA guidance. Safety depends on pharmacy compliance with USP standards and state oversight. Always verify your pharmacy's licensure and discuss any concerns with your healthcare provider.

Will brand-name Ozempic or Wegovy supply shortages return?

Brand-name GLP-1 supply remains stable as of 2024, though supply chains can shift. Compounding provides an alternative pathway if shortages recur, which is why the FDA maintains this regulatory option for 503A pharmacies.

How much can I expect to pay for compounded semaglutide?

PlexusDx compounded semaglutide injection ranges from $149 per month, significantly lower than typical brand-name costs. Pricing varies by dose, frequency, and pharmacy. Most compounded semaglutide is not insurance-covered and requires patient payment.

What should I ask my provider before choosing compounded semaglutide?

Ask whether compounded versus brand aligns with your clinical needs, what monitoring they recommend, how they verify pharmacy quality, and whether your medical history favors one pathway. Discuss any previous GLP-1 responses or metabolic concerns relevant to treatment selection.

Can genetic testing help me decide between compounded and brand semaglutide?

The Precision Peptide Genetic Test reveals predispositions in GLP-1 and metabolic pathways that may help provide context for your provider discussion. Genetic variants don't determine which medication source to choose, but they can inform a more personalized conversation about treatment approach and monitoring.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.